Neurovance accepts takeover bid from Otsuka

3 March 2017

Privately-held US firm Neurovance, which is focused on attention-deficit hyperactivity disorder (ADHD) and related disorders, has signed a definitive agreement to be acquired by Japanese drug major Otsuka Pharmaceutical (TYO: 4578)’

Under the terms of the agreement, Otsuka will pay Neurovance $100 million up front in cash,plus up to $150 million in additional payments contingent on the achievement of development and regulatory approval milestones, plus additional future payments contingent on achievement of sales milestones. The transaction is expected to close in the second quarter of 2017, subject to customary closing conditions.

Neurovance is based in Cambridge, Massachusetts, and was established as a spin-off from Euthymics Bioscience in 2011.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK